ClinicalTrials.gg
RecruitingNCT05066178TxMVASD+CASUpdated Mar 30, 2026

Speech Treatment for Minimally Verbal Children With ASD and CAS

An interventional study of CAS Treatment for Minimally Verbal Children with Autism in Developmental Verbal Dyspraxia and Autism Spectrum Disorder, sponsored by MGH Institute of Health Professions. Recruiting at 1 site in United States. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by MGH Institute of Health Professions · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Study summary

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Read the detailed description

Although one in four children with autism remain minimally verbal past age five, not all the factors that limit spoken language in these minimally verbal children are known. One powerful contributor may be a motor speech disorder, Childhood Apraxia of Speech (CAS). CAS is an impairment in the ability to plan and sequence for speech, which makes speech inconsistent and imprecise. This project proposes to investigate whether CAS makes the speech of minimally verbal children with autism unintelligible, and then to test whether treating the CAS improves children's speech.

First, a cohort of 20 minimally verbal children with both autism and CAS is identified. The prediction is that the more severe the CAS, the more inconsistent and imprecise a child's speech, and therefore the lower their intelligibility will be. Then, a set of mono- and bisyllabic words is selected that contain the disordered movements that each child shows and use those in treatment.

Treatment will take the form of 15 one-hour sessions where speech practice is embedded in a naturalistic, play-based milieu that is centered on each child's own developmental level. It will involve principles of motor learning (intensive practice of a few words, sometimes all in a row and sometimes mixed up). Different types of cues (touch cues, simultaneous production, etc.) will also be employed to help children say their words correctly, fading back these supports as the child's speech improves. Both of these techniques have been shown to be effective for treating CAS.

Our outcome measures will include both (1) "by-ear" assessments of intelligibility and (2) acoustic and kinematic measurements of children's speech after 15 treatment sessions. The findings will inform clinical practice for minimally verbal children with autism and may lead to the development of novel interventions for this severely affected population.

02

Conditions studied

  • Developmental Verbal Dyspraxia
  • Autism Spectrum Disorder

Keywords

  • childhood apraxia of speech
  • autism
  • motor speech disorder
  • speech development
03

In context

Apraxias

65 studies on the registry are indexed under Apraxias; 21 are open to participants now.

This study's planned enrollment of 20 is below the median of 32 across 50 interventional studies indexed under Apraxias.

Browse Apraxias studies →

Lead sponsor

MGH Institute of Health Professions is the lead sponsor of 19 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for Autism Spectrum Disorder
  • Able to correctly repeat at least 2 syllables
  • Meets criteria for Childhood Apraxia of Speech
  • Lives in an environment where child is exposed to English at least 50% of the time

Exclusion criteria

Exclusion Criteria:

  • Poorly controlled seizures
  • Factors such as blindness or deafness that contribute to minimally verbal status
  • Lives in an environment where English is not spoken at least 50% of the time
  • Child experiences behavioral challenges that preclude participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CAS Treatment for MV ASD

    Participants will receive CAS treatment, modified for minimally verbal children with autism

    Behavioral: CAS Treatment for Minimally Verbal Children with Autism

Interventions

  • BehavioralCAS Treatment for Minimally Verbal Children with Autism

    Treatment involves principles of motor learning embedded in a naturalistic developmental milieu

06

What researchers measure

Primary outcomes

  1. Attempts Correct

    Number or percent of target items that were produced correctly

    Time frame: 5 weeks

  2. Phonemes Correct

    Number or percent of phonemes (vowels, consonants) in the target items that were produced correctly

    Time frame: 5 weeks

Secondary outcomes

  1. Lip aperture movement variability

    Amount of variability in lip opening area during production of multiple attempts at the same target

    Time frame: 5 weeks

  2. Phoneme distinctiveness

    Acoustic distinctiveness of different phonemes

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05066178
Lead sponsor
MGH Institute of Health Professions
Responsible party
Karen Chenausky, Ph.D., CCC-SLP (Assistant Professor, MGH Institute of Health Professions) — Principal investigator
First posted
Oct 4, 2021
Start date
May 1, 2024
Primary completion
Apr 30, 2030 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Mar 30, 2026

Study contacts

Karen V Chenausky, Ph.D.
Contact
kvchenausky@mghihp.edu
617-726-2405
Michael Moody
Contact
mjmoody@partners.org
617-643-4658

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion